{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:38:32Z","timestamp":1787017112963,"version":"build-2736575974"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,6,17]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the use and safety of subcutaneous (SC) antibiotics for infection and symptom control in the palliative setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective chart review of the use of SC antibiotics since it was introduced to our palliative care service 7 years ago. All records were examined to ascertain therapeutic aim and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SC antibiotics were administered to 87 patients (79% had cancer) on 112 occasions (for infection, 105\/112, or symptom control, 7\/112) in the inpatient hospice or home. 85% wanted to avoid hospitalisation and requested active treatment in situ. Reasons for SC rather than intravenous administration included venous fragility and lack of an available cannulator. Piperacillin\/tazobactam was the most common antibiotic given. Of the occasions when treating for infection, the respiratory tract was the most common site; half survived beyond 21 days. Of those used for symptoms, antibiotics appeared helpful in 3\/7. Adverse events led to discontinuation in 7\/112 (\n                      <jats:italic>Clostridium difficile<\/jats:italic>\n                      , generalised rash or SC site problems in 1, 1 and 5\/112, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SC antibiotics appear well tolerated in the palliative setting and could be a useful option in selected patients who want to avoid hospitalisation but receive active treatment in situ. Thus, we believe that further research is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2025-005676","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:20:23Z","timestamp":1751030423000},"page":"spcare-2025-005676","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Subcutaneous antibiotics in palliative medicine: Retrospective chart review"],"prefix":"10.1136","author":[{"given":"John","family":"Curtin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7799-0456","authenticated-orcid":false,"given":"Keith","family":"Eldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8892-7307","authenticated-orcid":false,"given":"Mary-Elodine","family":"D\u2019silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-6310","authenticated-orcid":false,"given":"Paul","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"2025062710201825000_spcare-2025-005676v1.1","doi-asserted-by":"publisher","DOI":"10.5301\/jva.5000282"},{"key":"2025062710201825000_spcare-2025-005676v1.2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cmi.2014.11.017","article-title":"Subcutaneously administered antibiotics: a national survey of current practice from the French Infectious Diseases (SPILF) and Geriatric Medicine (SFGG) society networks","volume":"21","author":"Forestier","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2025062710201825000_spcare-2025-005676v1.3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jamda.2020.04.035","article-title":"Subcutaneous Antibiotic Therapy: The Why, How, Which Drugs and When","volume":"22","author":"Hern\u00e1ndez-Ruiz","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"2025062710201825000_spcare-2025-005676v1.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkad018","article-title":"Subcutaneously administered antibiotics: a review (addendum)","volume":"78","author":"Cassir","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025062710201825000_spcare-2025-005676v1.5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/dkae398","article-title":"Safety, tolerability and pharmacokinetics of subcutaneous meropenem as an alternative to intravenous administration","volume":"80","author":"Murray","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025062710201825000_spcare-2025-005676v1.6","doi-asserted-by":"publisher","DOI":"10.1159\/000238342"},{"key":"2025062710201825000_spcare-2025-005676v1.7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.medmal.2019.10.002","article-title":"Subcutaneous teicoplanin in staphylococcal bone and joint infections","volume":"50","author":"Destrem","year":"2020","journal-title":"Med Mal Infect"},{"key":"2025062710201825000_spcare-2025-005676v1.8","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1093\/jac\/dkz385","article-title":"Is the subcutaneous route an alternative for administering ertapenem to older patients? PHACINERTA study","volume":"74","author":"Roubaud Baudron","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025062710201825000_spcare-2025-005676v1.9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/jgs.18786","article-title":"Safety of subcutaneous versus intravenous ceftriaxone administration in older patients: A retrospective study","volume":"72","author":"Pardo","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"2025062710201825000_spcare-2025-005676v1.10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jamda.2019.08.010","article-title":"Safety of Subcutaneous Piperacillin\/Tazobactam Administration Compared to Intravenous Administration: Propensity Score-Matched Cohort Study","volume":"21","author":"Kobayashi","year":"2020","journal-title":"J Am Med Dir Assoc"},{"key":"2025062710201825000_spcare-2025-005676v1.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002558"},{"key":"2025062710201825000_spcare-2025-005676v1.12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00520-018-4090-8","article-title":"Antimicrobial therapy in palliative care: an overview","volume":"26","author":"Macedo","year":"2018","journal-title":"Support Care Cancer"},{"key":"2025062710201825000_spcare-2025-005676v1.13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/02692163231162889","article-title":"Antibiotic therapy is associated with adverse drug events among older adults with advanced cancer: A cohort study","volume":"37","author":"Datta","year":"2023","journal-title":"Palliat Med"},{"key":"2025062710201825000_spcare-2025-005676v1.14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1177\/10499091231156866","article-title":"Effectiveness of Subcutaneous Administration of Antibiotics to Control Infections in Elder Palliative Patients: A Systematic Review","volume":"40","author":"S\u00e1nchez-C\u00e1rdenas","year":"2023","journal-title":"Am J Hosp Palliat Care"},{"key":"2025062710201825000_spcare-2025-005676v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(98)00010-4"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2025-005676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:20:26Z","timestamp":1751030426000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2025-005676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":15,"alternative-id":["10.1136\/spcare-2025-005676"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2025-005676","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}